ONWARD1

If you decide to join this study, your participation will last for at least 28 weeks and it will be broken up into 4 periods:

• Screening period
• Study drug period
• Follow-up period
• Long-term extension period

During the screening period, you will visit our clinic for a physical exam and to have some tests done to find out if you are eligible. If you meet the study's criteria, you will proceed to the study drug period. During this period, you will get a random assignment (fair, equal chance) to either:

• Take the study drug; OR
• Take apremilast; OR
• Take a placebo

The study drug period will last for 24 weeks. You will visit our clinic at least 6 times during the study drug period. These visits will last about 2 hours each time. If you were assigned to take a placebo, you will be switched the study drug after 16 weeks. If you are taking the study drug or apremilast, you will take these drugs for the entire study drug period. At the end of the study drug period, we will assess your eligibility to join the long-term extension period:

• If you are not eligible for the long-term extension period, you will enter the follow-up period and we will keep in touch with you to see how you are doing.
• If you are eligible for the long-term extension period, you will have the option of continuing to take the study drug indefinitely. You can take the study drug for as long as you feel that you are getting a benefit, or until the study is terminated for any reason, or until the study drug is approved and becomes commercially available in the United States (whichever comes first).

For people who choose to join the long-term extension period, the follow-up period will begin whenever your study participation ends.